Menu

Corning Introduces New 1536-well Spheroid Microplate

High-throughput spheroid microplate benefits cancer research, drug screening

Feb 13, 2019
CORNING INCORPORATED

Corning Incorporated (NYSE: GLW) has expanded its spheroid microplate product offerings with the introduction of a unique 1536-well plate designed specifically for growing spheroid cell cultures. The Corning® 1536-well Spheroid Microplate helps scientists generate a higher volume of spheroids for high-throughput screening, which is especially beneficial in cancer research and drug testing. 

To help streamline work with 3D cell cultures in an automated environment, the 1536-well spheroid microplate features a novel and proprietary design that allows scientists to generate, culture, assay, and analyze 3D multicellular spheroids in one microplate. The spheroid microplate eliminates the need for a transfer step in visualization or biochemical assays, reducing the risk of cell damage or loss. The newer spheroid microplate format, in addition to Corning’s current 96- and 384-well formats, is compatible with most high-throughput screening instruments. 

As with all Corning spheroid microplates, the 1536-well microplate features round well bottoms and a Corning Ultra-Low Attachment (ULA) surface coating to enable uniform, centered, single-spheroid formation across all wells with a simple and easy to use “plug and play” protocol. It is also optimized for visualization with an optically clear well-bottom and black opaque microplate body to reduce well-to-well crosstalk.

“The 1536-well format takes spheroid plates out of the research lab and into high-throughput screening,” said Dr. Keith R. Olson, global director of business operations for Corning Life Sciences. “This enables researchers to drive a larger volume of compounds through drug screening in less time, using a more physiologically relevant 3D cell culture and thereby potentially accelerating the research and drug discovery process.” 

Corning continues to advance the science of 3D cell culture by bringing to market innovative solutions that provide easier access to in vivo-like 3D models, such as spheroid microplates, Corning Matrigel® matrix, and Transwell® permeable supports. Corning is committed to providing solutions for researchers in critical areas like cancer biology, tissue engineering, and regenerative medicine to help them bring safe, effective drugs and therapies to market in less time with greater certainty.

To learn more about Corning Life Sciences products, contact a customer service representative at (800) 492-1110; outside the United States, call (978) 442-2200; or visit www.corning.com/lifesciences. To learn more about Corning’s 3D Spheroid Microplate products, please visit: www.corning.com/spheroid.

Caution Concerning Forward-Looking Statements

This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effects of acquisitions, dispositions and other similar transactions by the Company, the effect of global business, financial, economic and political conditions; tariffs and import duties; currency fluctuations between the U.S. dollar and other currencies, primarily the Japanese yen, New Taiwan dollar, euro, Chinese yuan, and South Korean won; product demand and industry capacity; competitive products and pricing; availability and costs of critical components and materials; new product development and commercialization; order activity and demand from major customers; the amount and timing of our cash flows and earnings and other conditions, which may affect our ability to pay our quarterly dividend at the planned level or to repurchase shares at planned levels; possible disruption in commercial activities due to terrorist activity, cyber-attack, armed conflict, political or financial instability, natural disasters, or major health concerns; unanticipated disruption to equipment, facilities, IT systems or operations; effect of regulatory and legal developments; ability to pace capital spending to anticipated levels of customer demand; rate of technology change; ability to enforce patents and protect intellectual property and trade secrets; adverse litigation; product and components performance issues; retention of key personnel; customer ability, most notably in the Display Technologies segment, to maintain profitable operations and obtain financing to fund their ongoing operations and manufacturing expansions and pay their receivables when due; loss of significant customers; changes in tax laws and regulations including the Tax Cuts and Jobs Act of 2017; and the potential impact of legislation, government regulations, and other government action and investigations.

For a complete listing of risks and other factors, please reference the risk factors and forward-looking statements described in our annual reports on Form 10-K and quarterly reports on Form 10-Q. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.